# Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer

> **NCT00678509** · PHASE1,PHASE2 · TERMINATED · sponsor: **Tokyo University** · enrollment: 14 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** TTK peptide mixed with Montanide ISA 51

## Key facts

- **NCT ID:** NCT00678509
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 14 (ESTIMATED)
- **Why stopped:** Lack of financial support
- **Last updated:** 2009-12-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00678509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00678509, "Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00678509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*